The stock of Orion Engineered Carbons S.A. (NYSE:OEC) is a huge mover today! The stock decreased 1.77% or $0.36 during the last trading session, reaching $19.96. About 99,021 shares traded. Orion Engineered Carbons S.A. (NYSE:OEC) has risen 1.61% since March 19, 2018 and is uptrending. It has underperformed by 2.76% the S&P500. Some Historical OEC News: 17/05/2018 – ORION ENGINEERED CARBONS SA – QTRLY ADJ EPS $0.52; 09/04/2018 – S&P: ORION ENGINEERED CARBONS S.A. BB RATING AFFIRMED; 14/05/2018 – Cardinal Capital Buys New 1.2% Position in Orion Engineered; 15/05/2018 – Brenner West Capital Advisors Buys 1.4% of Orion Engineered; 17/05/2018 – ORION ENGINEERED CARBONS SA – QTRLY TOTAL VOLUMES INCREASED BY 4.0% TO 286.1 KMT; 05/03/2018 Orion Announces Filing of Annual Report for the Year Ended December 31, 2017; 17/05/2018 – Orion Engineered Carbons 1Q EPS 40c; 09/04/2018 – S&P REVISES ORION ENGINEERED CARBONS S.A. OUTLOOK TO ‘POSITIVE’ FROM ‘STABLE’; RATING ‘BB’; 11/04/2018 – Moody’s Changes Orion Outlook To Positive; Affirms Ba3 Cfr; 10/04/2018 – Orion Engineered Closes Above 50-Day Moving Average: TechnicalsThe move comes after 5 months negative chart setup for the $1.20 billion company. It was reported on Mar, 19 by Barchart.com. We have $18.36 PT which if reached, will make NYSE:OEC worth $95.84 million less.
Among 4 analysts covering ChemoCentryx (NASDAQ:CCXI), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ChemoCentryx had 4 analyst reports since November 12, 2018 according to SRatingsIntel. The rating was initiated by Leerink Swann with “Buy” on Thursday, February 14. The company was maintained on Monday, November 12 by Canaccord Genuity. H.C. Wainwright maintained it with “Buy” rating and $23 target in Tuesday, March 12 report. See ChemoCentryx, Inc. (NASDAQ:CCXI) latest ratings:
12/03/2019 Broker: H.C. Wainwright Rating: Buy New Target: $23 Maintain
14/02/2019 Broker: Leerink Swann Rating: Buy Initiate
11/02/2019 Broker: PiperJaffray Rating: Overweight New Target: $20 Initiates Coverage On
12/11/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $18 New Target: $20 Maintain
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $595.08 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It currently has negative earnings. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.
The stock increased 5.01% or $0.54 during the last trading session, reaching $11.32. About 1.86 million shares traded or 449.06% up from the average. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 12.22% since March 19, 2018 and is uptrending. It has outperformed by 7.85% the S&P500. Some Historical CCXI News: 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS); 09/03/2018 – CHEMOCENTRYX SEES 2018 CASH & INVESTMENTS USE $65M-$75M; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 13/03/2018 – CHEMOCENTRYX INC CCXI.O : JP MORGAN RAISES TARGET PRICE TO $16 FROM $13; 03/04/2018 – ChemoCentryx Presenting at Conference Apr 9; 09/05/2018 – CHEMOCENTRYX INC – QTRLY DILUTED NET LOSS PER COMMON SHARE $0.19; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 09/03/2018 – CHEMOCENTRYX INC QUARTERLY SHR $0.80; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA
More important recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Nasdaq.com which released: “ChemoCentryx (CCXI) Reports Q4 Loss, Lags Revenue Estimates – Nasdaq” on March 11, 2019, also Nasdaq.com published article titled: “ChemoCentryx (CCXI) Looks Good: Stock Adds 5.5% in Session – Nasdaq”, Nasdaq.com published: “After-Hours Earnings Report for March 11, 2019 : ADT, COUP, SFIX, DRNA, AVD, PETQ, CCXI, LXFR, MG, OXFD, FRTA, KALA – Nasdaq” on March 11, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) was released by: Globenewswire.com and their article: “New Research: Key Drivers of Growth for Ellie Mae, Spotify Technology SA, Bristow Group, Teradata, ChemoCentryx, and AgroFresh Solutions â€” Factors of Influence, Major Initiatives and Sustained Production – GlobeNewswire” with publication date: February 26, 2019.
Investors sentiment decreased to 0.93 in 2018 Q4. Its down 0.05, from 0.98 in 2018Q3. It dropped, as 7 investors sold ChemoCentryx, Inc. shares while 38 reduced holdings. 18 funds opened positions while 24 raised stakes. 27.13 million shares or 1.23% more from 26.80 million shares in 2018Q3 were reported. Millennium Ltd Liability Co holds 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 16,813 shares. Rhumbline Advisers has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). Zebra Mgmt Ltd holds 14,396 shares. Moreover, Swiss Bancorporation has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 38,400 shares. Smith Asset Mgmt Gru Ltd Partnership owns 22,897 shares. Metropolitan Life Insur New York has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). 126,200 are held by Spark Inv Mngmt Llc. Credit Suisse Ag invested in 0% or 10,418 shares. 257 were accumulated by Tower Capital Limited Liability Corp (Trc). Ny State Common Retirement Fund reported 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Blackrock has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). 33,717 are held by Trexquant Lp. Strs Ohio holds 0% in ChemoCentryx, Inc. (NASDAQ:CCXI) or 55,800 shares. Geode Mngmt Limited Co has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). Alps has 0.01% invested in ChemoCentryx, Inc. (NASDAQ:CCXI).
Since October 16, 2018, it had 0 buys, and 8 insider sales for $87.64 million activity. $158,790 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) was sold by Cappel Markus J.. KANAYA SUSAN M sold 37,893 shares worth $457,747. On Thursday, January 10 the insider Schall Thomas J. sold $447,092. The insider GLAXOSMITHKLINE PLC sold 7.34M shares worth $85.85 million.
More notable recent Orion Engineered Carbons S.A. (NYSE:OEC) news were published by: Finance.Yahoo.com which released: “How Does Orion Engineered Carbons, S.A. (NYSE:OEC) Fare As A Dividend Stock? – Yahoo Finance” on February 19, 2019, also Seekingalpha.com with their article: “Orion Engineered Carbons declares $0.20 dividend – Seeking Alpha” published on March 01, 2019, Fool.com published: “Why Orion Engineered Carbons Stock Is Plunging Today – The Motley Fool” on March 08, 2019. More interesting news about Orion Engineered Carbons S.A. (NYSE:OEC) were released by: Benzinga.com and their article: “Benzinga’s Top Upgrades, Downgrades For March 11, 2019 – Benzinga” published on March 11, 2019 as well as Benzinga.com‘s news article titled: “50 Stocks Moving In Friday’s Mid-Day Session – Benzinga” with publication date: March 08, 2019.
Among 2 analysts covering Orion Engineered Carbons (NYSE:OEC), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Orion Engineered Carbons had 4 analyst reports since November 20, 2018 according to SRatingsIntel. The stock of Orion Engineered Carbons S.A. (NYSE:OEC) has “Buy” rating given on Tuesday, November 20 by UBS. Barclays Capital maintained Orion Engineered Carbons S.A. (NYSE:OEC) rating on Monday, March 11. Barclays Capital has “Hold” rating and $26 target.
Orion Engineered Carbons S.A., together with its subsidiaries, produces and sells carbon black products in Germany, the United States, South Korea, Brazil, South Africa, the rest of Europe, and internationally. The company has market cap of $1.20 billion. It operates through two divisions, Specialty Carbon Black and Rubber Carbon Black. It has a 10.03 P/E ratio. The firm offers post-treated specialty carbon black grades for coatings and printing applications; and various conductive carbon black grades for use in polymer and printing applications, as well as in silicon, non-woven textile, building material, battery electrodes metallurgical, agrochemical, and carbon brush applications.